Contribute Try STAT+ Today

Global Blood Therapeutics (GBT) is taking an unprecedented regulatory gamble to win approval for a new drug to treat sickle cell disease. Are investors underestimating the risk that this effort blows up?

It looks that way. The South San Francisco-based biotech disclosed mixed results from a Phase 3 clinical trial in late June. Since then, Global Blood executives have been on the road with investors, talking up an FDA submission strategy for its drug, called voxelotor, that has never been tried before in sickle cell disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.